Related Experiment Video

Updated: Jun 30, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K

Dbl family RhoGEFs in cancer: different roles and targeting strategies

Xin-Yi Chen1, Ao-Yu Cheng1, Zi-Ying Wang2

  • 1Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Biochemical Pharmacology
|March 18, 2024
PubMed

Insights

Rho guanine nucleotide exchange factors (RhoGEFs), particularly the Dbl family, are crucial in cancer development. Targeting these RhoGEFs presents promising new therapeutic strategies for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Small Ras homologous guanosine triphosphatase (Rho GTPase) proteins are implicated in tumorigenesis.
  • Rho guanine nucleotide exchange factors (RhoGEFs) regulate Rho GTPase activity and are involved in tumor development.
  • RhoGEFs are classified into Dbl and dedicator of cytokinesis (Dock) families, with Dbl family members showing abnormal expression in cancers.

Purpose of the Study:

  • To review the structural characteristics of Dbl family RhoGEFs.
  • To summarize the roles of Dbl family RhoGEFs in cancer.
  • To highlight therapeutic strategies targeting Dbl family RhoGEFs.

Main Methods:

  • Literature review focusing on Dbl family RhoGEFs.
  • Analysis of structural features and cancer-related functions.
  • Identification of therapeutic targets within Dbl family RhoGEFs.

Main Results:

  • Dbl family RhoGEFs exhibit diverse structures and functions.
  • Abnormal expression of Dbl family members correlates with poor cancer prognosis.
  • Specific Dbl family members like Ect2, Tiam1/2, P-Rex1/2, Vav1/2/3, Trio, KALRN, and LARG are key players in cancer.

Conclusions:

  • Dbl family RhoGEFs are significant contributors to cancer development.
  • Targeting Dbl family RhoGEFs offers novel therapeutic avenues for cancer treatment.
Keywords:
CancerDbl familyRho guanine nucleotide exchange factorsTargeting strategy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

151

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K